GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Rhythm Biosciences Ltd (ASX:RHY) » Definitions » EBITDA Margin %

Rhythm Biosciences (ASX:RHY) EBITDA Margin % : 0.00% (As of Dec. 2023)


View and export this data going back to 2017. Start your Free Trial

What is Rhythm Biosciences EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Rhythm Biosciences's EBITDA for the six months ended in Dec. 2023 was A$-2.67 Mil. Rhythm Biosciences's Revenue for the six months ended in Dec. 2023 was A$0.00 Mil. Therefore, Rhythm Biosciences's EBITDA margin for the quarter that ended in Dec. 2023 was 0.00%.


Rhythm Biosciences EBITDA Margin % Historical Data

The historical data trend for Rhythm Biosciences's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rhythm Biosciences EBITDA Margin % Chart

Rhythm Biosciences Annual Data
Trend Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
EBITDA Margin %
Get a 7-Day Free Trial - - - - -

Rhythm Biosciences Semi-Annual Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Rhythm Biosciences's EBITDA Margin %

For the Diagnostics & Research subindustry, Rhythm Biosciences's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rhythm Biosciences's EBITDA Margin % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Rhythm Biosciences's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Rhythm Biosciences's EBITDA Margin % falls into.



Rhythm Biosciences EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Rhythm Biosciences's EBITDA Margin % for the fiscal year that ended in Jun. 2023 is calculated as

EBITDA Margin %=EBITDA (A: Jun. 2023 )/Revenue (A: Jun. 2023 )
=-11.352/0
= %

Rhythm Biosciences's EBITDA Margin % for the quarter that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=-2.67/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Rhythm Biosciences  (ASX:RHY) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Rhythm Biosciences EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Rhythm Biosciences's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Rhythm Biosciences (ASX:RHY) Business Description

Traded in Other Exchanges
Address
30 Flemington Road, Bio21 Institute, Parkville, Melbourne, VIC, AUS, 3010
Rhythm Biosciences Ltd is a medical diagnostics technology company. It is engaged in developing and commercializing Australian medical diagnostics technology for sale to national and international markets. Its product includes ColoSTAT a proposed diagnostic blood test for screening for colorectal cancer. Geographically, the company operates only in Australia.

Rhythm Biosciences (ASX:RHY) Headlines

No Headlines